当前位置： SCI文献检索 > Brachytherapy期刊下所有文献 > Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.

Abstract：

PURPOSE:Androgen deprivation therapy (ADT) has been shown to improve survival for men with unfavorable-risk prostate cancer (PCa). We investigated the utilization and factors associated with the omission of ADT in radiation-managed high-risk PCa. METHODS AND MATERIALS:We used the National Cancer Database to identify men with National Comprehensive Cancer Network high-risk PCa treated with external beam radiation therapy (EBRT) with or without brachytherapy boost from 2004 to 2012. Multivariable logistic regression adjusting for clinical and sociodemographic factors was used to identify independent predictors for ADT use. RESULTS:A total of 57,968 radiation-treated high-risk PCa men were included in our analysis. There were 49,363 patients (85.2%) treated with EBRT alone and 8605 patients (14.8%) treated with EBRT plus brachytherapy boost. Overall, 77% of men received ADT. In multivariable regression analysis, the use of brachytherapy boost was associated with a significantly lower utilization of ADT (70% vs. 78%; adjusted odds ratio [AOR]: 0.65; 95% CI: 0.62-0.69; p-Value <0.0001), as was treatment at an academic vs. nonacademic center (AOR: 0.90; 95% CI: 0.86-0.95; p-Value <0.0001) and treatment in 2010-2012 compared to 2004-2006 (AOR: 0.85; 95% CI: 0.81-0.90; p-Value <0.0001). Conversely, greater ADT use was seen with higher Gleason scores, PSA, and T-category (all p-Values <0.001). CONCLUSIONS:Approximately one in four men with radiation-managed high-risk PCa do not receive ADT, which may reflect concerns about its toxicity profile despite known improvements in overall survival. Practice patterns suggest that some providers believe dose escalation through brachytherapy boost may obviate the need for ADT in some high-risk patients, but this hypothesis requires further testing.

journal_name

Brachytherapy

journal_title

Brachytherapy

authors

Chen YW,Muralidhar V,Mahal BA,Nezolosky MD,Beard CJ,Choueiri TK,Hoffman KE,Martin NE,Orio PF,Sweeney CJ,Feng FY,Trinh QD,Nguyen PL

doi

10.1016/j.brachy.2016.07.001

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

695-700

issue

eissn

1538-4721

issn

1873-1449

pii

S1538-4721(16)30506-2

journal_volume

pub_type

杂志文章

在线工具

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.